Member Info for TheDogFarther

Next the M62, that really will be big money.

Blow and Go, can i ask why you didnt snap them up this afternoon ?

I must say i have come to really appreciate the valuable and different perspective lse03 adds to the board. Hmm, Navantia supplying a growing Australian navy. I bet BAe would like a piece of that pie.

Looks like Stokey is back in the POTing shed.

Now the shipyard has so much work, H&W must extend its fabrication halls

The strong change in sentiment that we are currently experiencing multiplied by iis coming in after the financing agreement could take us there.

Ahh, i apologise. In that case you may be right.

Mikey,i have to say i disagree. I dont believe HARL will get to £1 before the IslandMagee decision, which I expect to come after the funding agreement.

Kaeren, ohh you charmer. I will drink to that.

HmmStandon, they would certainly Float the Boat.

Forest, yes that would certainly Go Down well.

The Tree Shake of Death is a great name for a new ****tail at the Crown pub for the £1 party. What would the ingredients be ?

I thought the 10p MBO topped the Tree Shake of Death.

SHAFTED BY WHO ?

I expect that they were waiting for the 10p MBO.

https://www.nicholsonspubs.co.uk/restaurants/scotlandandnorthernireland/thecrownliquorsaloonbelfast#/
If you sign up Mary , you get a free ****tail on your next visit.

Sounds good , will have a look on website.

It has to happen by September as ive booked the Crown Bar. Your paying (:

What does this mean. Well first of all it means a valuation of approximately £500m .

I found this very interesting in helping myself understand the benefits of this approach.

“Even if our primary endpoint was not achieved, there's still information in that data that can help us as we think about the next trial we might want to do. It could be that we want to test this drug in a different population. It could be that we're thinking about other drugs that we might want to be testing. Post-hoc analyses are questions that we try to answer with our data after the study had finished and was not the intent of that particular study”

In a post-hoc analysis of a clinical trial, researchers will often further divide data to see if the drug had benefits for certain groups. Consider an example where the initial data for a trial has shown no benefit in the group that received the drug when compared to a placebo group. A researcher conducting a post-hoc analysis might look at only people who are under a certain age, or only people of a certain sex, and find that there is evidence that in this smaller group, that participants did appear to decline slower or survive longer.